The US Food and Drug Administration (FDA) approved generic Crestor (rosuvastitin calcium) manufactured by Actavis. Crestor is indicated use in combination with diet for treatment of high triglycerides (hypertriglyceridemia) in adults and for treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia), a disorder associated with improper breakdown of cholesterol and triglycerides. Crestor is also indicated either alone or in combination with other cholesterol treatment(s) for adult patients with homozygous familial hypercholesterolemia, a disorder associated with high low-density lipoprotein (LDL) cholesterol.
The most common side effects reported by participants taking Crestor in the clinical trials included headache, pain in muscles (myalgia), abdominal pain, abnormal weakness (asthenia), and nausea. Rosuvastatin calcium should not be used in women who are pregnant or may become pregnant as it may cause fetal harm and should not be used by women who are nursing their infants.